Lilly's Necitumumab: FDA Panel To Weigh Modest Survival Benefit Against Thromboembolic Risks
This article was originally published in The Pink Sheet Daily
Executive Summary
Is benefit/risk profile in squamous non-small cell lung cancer impacted by Phase III results from trial in non-squamous population that was halted early due to safety issues?
You may also be interested in...
Lilly's Portrazza: Box Warning + Modest Efficacy Could Still = Sales Success
EGFR inhibitor necitumumab may find place in first-line squamous type non-small cell lung cancer market due to limited treatment options – at least for now.
Lilly’s Necitumumab Gains FDA Panel Blessing For Lung Cancer
If approved, post-marketing safety study likely to be required on use of prophylactic anticoagulation to head off thromboembolic events with the anti-EGFR agent.
Payback Time For Lilly? Erbitux Follow-on Succeeds In Squamous Lung Cancer Trial
Lilly’s necitumumab – gained through the company’s ImClone acquisition – demonstrates an overall survival benefit in the SQUIRE study against first-line metastatic squamous NSCLC. Pleasantly surprised by the outcome, some analysts start to expect blockbuster sales.